Table 2 Adjusted linear mixed models taking MNA values for every follow-up period as response
Fixed effects | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 |
|---|---|---|---|---|---|
Intercept | 24.5 | 25.8 | 25.7 | 25.6 | 26.3 |
(23.4; 25.2) | (24.6; 26.6) | (24.5; 26.4) | (24.4; 26.4) | (25.2; 27.2) | |
Follow-up period | −0.21 | −0.22 | −0.22 | −0.21 | −0.24 |
(−0.41; 0.42) | (−0.52; 0.38) | (−0.54; 0.34) | (−0.50; 0.40) | (−0.56; 0.31) | |
Intervention group | 0.61 | 0.63 | 0.47 | 0.64 | 0.52 |
(−0.51; 2.03) | (−0.48; 2.01) | (−0.64; 1.82) | (−0.46; 2.04) | (−0.57; 1.86) | |
Follow-up period*Intervention group | −0.21 | −0.19 | −0.19 | −0.21 | −0.18 |
(−0.96; 0.26) | (−0.89; 0.32) | (−0.88; 0.32) | (−0.92; 0.29) | (−0.85; 0.34) | |
Female | -- | −1.18 | −0.69 | −0.80 | −0.77 |
(−1.70; −0.56) | (−1.22; −0.13) | (−1.31; −0.17) | (−1.29; −0.18) | ||
Co-morbidity|| | -- | −1.42 | -- | -- | −0.83 |
(−2.02; −0.87) | (−1.42; −0.21) | ||||
Cognition impairment§, | -- | -- | −2.5 | -- | −2.26 |
(−3.11; 1.89) | (−2.83; −1.63) | ||||
Polifarmacy£ | -- | -- | -- | −1.18 | −0.70 |
(−1.84; −0.72) | (−1.34; −0.22) | ||||
Random effects | 1.23 | 1.13 | 1.02 | 1.13 | 0.93 |
(0.89; 1.54) | (0.76; 1.47) | (0.58; 1.39) | (0.75; 1.46) | (0.43; 1.33) |